Primary biliary cholangitis: Disease burden, treatments and RWD gaps
What real-world data reveals about the unique challenges of studying rare disease Primary biliary...
The therapeutic market that you know is shaped by the healthcare data that you can see. But when critical medical, specialty, clinical or longitudinal signals are absent from that view, the picture (and the decisions based on it) is less clear. ...
What real-world data reveals about the unique challenges of studying rare disease Primary biliary...
Healthcare marketing has reached an inflection point and for years, success was defined by reach:...
Capturing the true complexity of psoriasis in the real world Psoriasis is a common chronic...
Closed claims no longer reflect real-world GLP-1 treatment patterns GLP-1 utilization continues to...
As the new year begins, many patients refocus on weight management and long-term health goals. At...
Artificial intelligence is no longer something healthcare and life sciences teams are testing on...
Regulatory decision-making depends on evidence that reflects how medical products perform in...
Industry trends in ulcerative colitis research: a new path Ulcerative colitis is a chronic...
New research is challenging long-held assumptions about privacy-preserving record linkage (PPRL)....
Early signals indicate continued declines in influenza vaccination uptake and shifts in the...
In atopic dermatitis, 23% of new patient starts come from HCPs that brand teams either deprioritize or don’t have in their data at all. One in three top-decile prescribers in that same market saw zero new patient starts over a 22-month stretch. In ob...